文献速递免疫规划卫生政策与健康促进

模拟挪威水痘与带状疱疹联合免疫规划的影响

Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
PubMed 文献 · Vaccine · 2018-01-20

研究用基于外源性增强的进展性免疫公式的数学模型评估挪威水痘与带状疱疹多种免疫策略,包括普遍或针对性水痘疫苗接种单用或联合带状疱疹免疫及带状疱疹免疫单用,并比较现有减毒活疫苗与新型重组疫苗。结果显示普遍水痘疫苗接种单用在所有情景下均致带状疱疹发病率显著上升,仅重组疫苗带状疱疹免疫联合长保护期可缓解;青少年针对性水痘疫苗接种仅致带状疱疹发病率小幅上升,可被活疫苗尤其重组疫苗抵消,可能是普遍接种的合适替代。

要点

  • 普遍水痘疫苗接种单用在所有情景下均导致带状疱疹发病率显著上升。
  • 青少年针对性水痘疫苗接种仅致带状疱疹发病率小幅上升,可被活疫苗尤其重组疫苗抵消。
  • 作者认为青少年针对性水痘疫苗接种是唯一不预测影响带状疱疹流行病学的策略,或为普遍接种的合适替代。

核心结论

  • 基于当前对带状疱疹发病机制和外源性增强的认识,青少年针对性水痘疫苗接种是唯一不预测影响带状疱疹流行病学的策略,可能代表普遍接种的合适替代。
  • 结果旨在支持挪威及其他具有相似水痘-带状疱疹病毒流行病学国家的疫苗政策决策。

研究设计与样本

  • 研究使用基于外源性增强的进展性免疫公式的挪威水痘-带状疱疹病毒数学模型。
  • 评估了水痘与带状疱疹的完整替代免疫方案,包括普遍和针对性水痘疫苗接种单用或联合带状疱疹免疫及带状疱疹免疫单用。
  • 考虑了与挪威带状疱疹发病率一致的所有增强强度值,并比较现有减毒活疫苗与新型重组疫苗的表现。

主要发现

  • 普遍水痘疫苗接种单用在所有考虑的情景下均导致带状疱疹发病率显著上升。
  • 即使在增强强度最大有利假设下,该上升仅可通过平行使用重组疫苗进行带状疱疹免疫并假设长保护期来缓解。
  • 青少年针对性水痘疫苗接种导致带状疱疹发病率小幅上升,可被活疫苗和尤其重组疫苗抵消。

临床怎么用

  • 作者认为青少年针对性水痘疫苗接种可能代表普遍接种的合适替代。
  • 结果旨在支持挪威及其他具有相似水痘-带状疱疹病毒流行病学国家的疫苗政策决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adoption of varicella immunization in Europe is limited due to a predicted increase in the incidence of herpes zoster (HZ) resulting from a removal of exogenous boosting by varicella vaccination. Most available assessments of immunization strategies only considered universal varicella vaccination (alone or in combination with HZ by the live vaccine). The development of a new subunit recombinant zoster vaccine may provide new perspectives of HZ control. METHODS: We used a mathematical model for VZV in Norway based on the progressive immunity formulation of exogenous boosting. We evaluated a complete range of alternative immunization options against varicella and HZ including both universal and targeted varicella vaccination, either alone or with zoster immunization, and zoster immunization alone. We considered all values of the boosting intensity consistent with the Norwegian HZ incidence and compared the performance of the currently available live vaccine vs. a new recombinant vaccine. RESULTS: Universal varicella vaccination alone resulted in a marked increase in the incidence of HZ under all scenarios considered. Even under the most favorable hypotheses on the magnitude of the boosting intensity, this increase could be mitigated only by a parallel HZ immunization with a recombinant vaccine, assuming a long duration of protection. Targeted varicella immunization of adolescents resulted in a modest increase in the HZ incidence which could be counterbalanced by both the live and, especially, the recombinant vaccine. CONCLUSIONS: Given current knowledge on HZ pathogenesis and exogenous boosting, targeted varicella vaccination of adolescents was the only strategy that was not predicted to impact the epidemiology of HZ, and therefore it may represent a suitable alternative to universal vaccination. These results are aimed to support vaccine policy decisions in Norway and other countries with a similar VZV epidemiology.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Marchetti S, Guzzetta G, Flem E, et al. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. Vaccine. 2018. PMID: 29366704. doi:10.1016/j.vaccine.2018.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。